[go: up one dir, main page]

WO1997020554B1 - Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc - Google Patents

Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Info

Publication number
WO1997020554B1
WO1997020554B1 PCT/US1996/019447 US9619447W WO9720554B1 WO 1997020554 B1 WO1997020554 B1 WO 1997020554B1 US 9619447 W US9619447 W US 9619447W WO 9720554 B1 WO9720554 B1 WO 9720554B1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
compound
formula
treatment
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/019447
Other languages
French (fr)
Other versions
WO1997020554A1 (en
Filing date
Publication date
Priority claimed from US08/567,199 external-priority patent/US5646180A/en
Priority to UA98073527A priority Critical patent/UA61902C2/en
Priority to DE69633680T priority patent/DE69633680T2/en
Priority to EP96942917A priority patent/EP0866696B1/en
Priority to AU11486/97A priority patent/AU722850B2/en
Priority to DK96942917T priority patent/DK0866696T3/en
Priority to PL96327061A priority patent/PL187747B1/en
Priority to HU9903673A priority patent/HUP9903673A3/en
Priority to AT96942917T priority patent/ATE279922T1/en
Priority to BR9611861A priority patent/BR9611861A/en
Application filed filed Critical
Priority to JP9521449A priority patent/JP2000501713A/en
Priority to NZ324603A priority patent/NZ324603A/en
Priority to KR1019980704028A priority patent/KR19990071750A/en
Priority to APAP/P/1998/001340A priority patent/AP864A/en
Publication of WO1997020554A1 publication Critical patent/WO1997020554A1/en
Publication of WO1997020554B1 publication Critical patent/WO1997020554B1/en
Priority to NO19982556A priority patent/NO317837B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Methods and compositions for treating the central nervous system (CNS) effects of HIV, particularly AIDS related dementia.

Claims

AMENDED CLAIMS
[received by the International Bureau on 16 June 1997 (16 06 97), original claims 1-4 replaced by new claims 1-7 (1 pages)]
1. Use of a compound of Formula I
Figure imgf000003_0001
(I) for the treatment of CNS effects of a virus which depends on an aspartyl protease for an obligatory event in its life cycle.
2. Use of a compound of Formula I:
Figure imgf000003_0002
(I)
for the treatment of CNS effects of HIV.
AMENDED SHEET (ARTICLE 18| Use of a compound of Formula I
Figure imgf000004_0001
(I) for the preparation of a pharmaceutical composition to treat CNS effects of HIV.
4. The use according to claim 3, wherein the composition further comprises AZT, 3TC or both.
5. Use of a compound of Formula I:
Figure imgf000004_0002
( I ) for the inhibition of infectious HIV virion production in the CNS.
6. Use of a compound of Formula I:
Figure imgf000005_0001
(I) for the preparation of a pharmaceutical composition which can inhibit infectious HIV virion production in the CNS.
7. The use according to claim 6, wherein the composition further comprises AZT, 3TC or both.
PCT/US1996/019447 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc Ceased WO1997020554A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
UA98073527A UA61902C2 (en) 1995-12-05 1996-05-12 Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition
APAP/P/1998/001340A AP864A (en) 1995-12-05 1996-12-05 Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc.
JP9521449A JP2000501713A (en) 1995-12-05 1996-12-05 Treatment of CNS action of HIV using VX-478 alone or in combination with AZT or 3TC
AU11486/97A AU722850B2 (en) 1995-12-05 1996-12-05 Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
DK96942917T DK0866696T3 (en) 1996-12-05 1996-12-05 Treatment of HIV ZNS effects with VX-478 alone or in combination with AZT or 3TC
PL96327061A PL187747B1 (en) 1995-12-05 1996-12-05 Treatment of hiv infection effects occured in the central nervous system by means o vx-478 preparation used solely or in combination wit azt or 3tc
HU9903673A HUP9903673A3 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc
AT96942917T ATE279922T1 (en) 1995-12-05 1996-12-05 TREATMENT OF CNS EFFECTS OF HIV WITH VX-478, ALONE OR COMBINED WITH AZT OR 3TC
BR9611861A BR9611861A (en) 1995-12-05 1996-12-05 Treatment of hiv central nervous system effects with vx-478 alone or in combination with azt or 3tc
DE69633680T DE69633680T2 (en) 1995-12-05 1996-12-05 TREATMENT OF CNS EFFECTS OF HIV WITH VX-478, ALONE OR COMBINED WITH AZT OR 3TC
EP96942917A EP0866696B1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc
NZ324603A NZ324603A (en) 1995-12-05 1996-12-05 Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
KR1019980704028A KR19990071750A (en) 1995-12-05 1996-12-05 How to treat the central nervous system effect of human immunodeficiency virus with VX-478 alone or with VX-478 with zidovudine or 3TC
NO19982556A NO317837B1 (en) 1995-12-05 1998-06-04 Use of compound for the preparation of a drug for inhibiting an aspartyl protease dependent virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 1995-12-05
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV

Publications (2)

Publication Number Publication Date
WO1997020554A1 WO1997020554A1 (en) 1997-06-12
WO1997020554B1 true WO1997020554B1 (en) 1997-08-07

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019447 Ceased WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Country Status (23)

Country Link
US (1) US5646180A (en)
EP (1) EP0866696B1 (en)
JP (1) JP2000501713A (en)
KR (1) KR19990071750A (en)
CN (1) CN1203530A (en)
AP (1) AP864A (en)
AT (1) ATE279922T1 (en)
AU (1) AU722850B2 (en)
BR (1) BR9611861A (en)
CA (1) CA2238471A1 (en)
CZ (1) CZ291994B6 (en)
DE (1) DE69633680T2 (en)
ES (1) ES2231828T3 (en)
HU (1) HUP9903673A3 (en)
NO (1) NO317837B1 (en)
NZ (1) NZ324603A (en)
OA (1) OA10691A (en)
PL (1) PL187747B1 (en)
PT (1) PT866696E (en)
RU (1) RU2203658C2 (en)
UA (1) UA61902C2 (en)
WO (1) WO1997020554A1 (en)
ZA (1) ZA9610139B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EA001517B1 (en) * 1996-06-25 2001-04-23 Глаксо Груп Лимитед Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
HUP9903098A3 (en) * 1996-06-25 2000-01-28 Glaxo Group Ltd Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
JP2001525840A (en) * 1997-05-17 2001-12-11 グラクソ、グループ、リミテッド Antiviral combinations containing carbocyclic nucleosides 1592U89
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
MXPA02006134A (en) 1999-12-21 2002-12-13 Guilford Pharm Inc Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same.
EP1582180B1 (en) * 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
ES2363160T3 (en) 2004-07-27 2011-07-22 Gilead Sciences, Inc. NUCELOSIDIC PHOSPHONATE CONJUGATES AS ANTI-HIV AGENTS.
EP1845969A4 (en) * 2005-01-20 2010-04-28 Univ Rochester COMPOSITIONS AND METHOD FOR MITOCHONDRIAL HYPERPOLARIZATION IN NEUROLOGICAL DISEASE
US20090081318A1 (en) * 2005-12-23 2009-03-26 Gelbard Harris A Treatment of neuroads using inhibitors of glycogen synthase kinase (gsk)-3
EP2029528A1 (en) * 2006-04-19 2009-03-04 Abbott GmbH & Co. KG Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EA201790024A1 (en) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. MODULATORS OF TOLL-LIKE RECEPTORS FOR HIV TREATMENT
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
CN110573122A (en) 2016-12-14 2019-12-13 阿坦斯医疗保健产品公司 Absorbent laminate, absorbent core, and disposable articles utilizing the same, and related methods
WO2019231926A1 (en) 2018-05-28 2019-12-05 Attends Healthcare Products, Inc. Dryness layer laminate for absorbent articles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Similar Documents

Publication Publication Date Title
WO1997020554B1 (en) Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
CA2192433A1 (en) Anti-herpesvirus compounds and methods for identyfying, making and using same
RU98112594A (en) TREATING A HIV-CENTERED CENTRAL NERVOUS SYSTEM BY VX-478, ISOLATED EITHER IN COMBINATION WITH AZT OR ZTS
ATE392895T1 (en) USE OF RITONAVIR (ABT-538) TO IMPROVE THE PHARMACOKINETICS OF DRUGS METABOLIZED BY CYTOCHROME P450 AS PART OF THE TREATMENT OF AIDS
AU5242000A (en) Nematicidal trifluorobutenes
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
NZ324603A (en) Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
CA2075173A1 (en) Compounds and methods for inhibition of hiv and related viruses
CA2168447A1 (en) Compounds and methods for inhibition of hiv and related viruses
CA2258217A1 (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
IN2012DE00109A (en)
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
AU2838497A (en) Process for the preparation of substituted aryllactic acid- containing cyclodepsipeptides having 24 ring atoms
EP0306282A3 (en) Antiviral compositions derived from marine sponge epipolasis reiswigi and their methods of use
RU94039284A (en) Piperazine derivatives, process for preparation thereof, pharmcomposition and use thereof
WO1995014011A3 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
UA74324C2 (en) Forms of crystalline efavirentz and methods of treatment with use thereof
WO1998027930A3 (en) New use of aminopiperazine derivatives
CA2182675A1 (en) Limescale Removing Compositions
CA2027276A1 (en) Novel .alpha.-glucosidase inhibitors
CA2007261A1 (en) Novel tetralin derivatives
EP1690545A3 (en) Preparation of Product R and product so obtained
ES2054011T3 (en) A PROCESS FOR THE PREPARATION OF A COMPOUND, "LEUALACINA".
EP0739901A3 (en) Novel oligoribonucleotide derivatives and application thereof to antiviral agents